Citigroup Inc Alaunos Therapeutics, Inc. Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$0.12 - $0.5 $130 - $544	-1,089 Reduced 26.71%	2,988 $0
Q2 2023 Aug 10, 2023	BUY	$0.43 - $0.65 $576 - $871	1,341 Added 49.01%	4,077 $2,000
Q1 2023 May 11, 2023	SELL	$0.46 - $0.81 $97,639 - $171,929	-212,259 Reduced 98.73%	2,736 $1,000
Q4 2022 Feb 09, 2023	BUY	$0.5 - $261.0 $5,400 - $2.82 Million	10,800 Added 5.29%	214,995 $139,000
Q3 2022 Nov 10, 2022	BUY	$1.04 - $322.5 $201,323 - $62.4 Million	193,580 Added 1823.65%	204,195 $351,000
Q2 2022 Aug 10, 2022	SELL	$0.41 - $1.24 $4,842 - $14,645	-11,811 Reduced 52.67%	10,615 $13,000
Q1 2022 May 12, 2022	SELL	$0.62 - $1.17 $398,780 - $752,536	-643,194 Reduced 96.63%	22,426 $15,000
Q4 2021 Feb 10, 2022	BUY	$1.09 - $1.89 $146,312 - $253,698	134,232 Added 25.26%	665,620 $726,000
Q3 2021 Nov 10, 2021	BUY	$1.44 - $2.73 $765,198 - $1.45 Million	531,388 New	531,388 $967,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.